Acta Pharmaceutica Sinica B
|
2025, 15(12): 6714-6726
• Original articles •
Development of a novel 18F-labeled reversible-binding radioligand for imaging monoacylglycerol lipase with positron emission tomography
Full
Affiliations
Published: 2025-12-25
doi: 10.1016/j.apsb.2025.05.041
Outline
Monoacylglycerol lipase (MAGL) constitutes a crucial serine hydrolase within the endocannabinoid system, which has been suggested as a potential therapeutic target for the treatment of various neurodegenerative disorders. While MAGL inhibitors have entered the clinical arena, a highly selective and MAGL-specific positron emission tomography (PET) ligand holds promise to significantly facilitate clinical drug development by allowing the quantification of MAGL levels and the assessment of target occupancy in patients. Accordingly, this study aimed to develop a new series of reversible MAGL inhibitor candidates, based on a piperazinyl azetidine diamide scaffold. Compound 3 demonstrated the most promising performance characteristics in pharmacological evaluations compared to other MAGL inhibitor candidates. Subsequently, it was labeled with fluorine-18 and further assessed through autoradiography and PET imaging, as well as ex vivo biodistribution and metabolite analysis experiments in rodents. Compound 3 exhibited a heterogeneous radioactivity distribution, favorable brain uptake, and excellent in vivo binding specificity. Target occupancy studies with a therapeutic MAGL inhibitor demonstrated a dose-dependent PET signal reduction of [18F]3 in rat brains. In conclusion, [18F]3 ([18F]MAGL-2011) has the potential to serve as an effective MAGL PET ligand.
Monoacylglycerol lipase
/
MAGL
/
Serine hydrolase
/
PET
.
Development of a novel ¹⁸F-labeled reversible-binding radioligand for imaging monoacylglycerol lipase with positron emission tomography.
药学学报(英文版),
2025
, 15
(12)
: 6714
-6726
.
DOI: 10.1016/j.apsb.2025.05.041
.
Development of a novel 18F-labeled reversible-binding radioligand for imaging monoacylglycerol lipase with positron emission tomography[J].
Acta Pharmaceutica Sinica B,
2025
, 15
(12)
: 6714
-6726
.
DOI: 10.1016/j.apsb.2025.05.041
Year 2025 volume 15 Issue 12
28
0
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.apsb.2025.05.041
- Receive Date:2024-10-28
- Online Date:2026-10-25
- Published:2025-12-25